ETFs with QCOR as a Top 10 Holding*Sponsored by:
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|4.45%||SPDR S&P Pharmaceuticals ETF (XPH)||+9.12 (16.66%)|
|2.89%||PowerShares Exchange-Traded Fund Trust II PowerShares S&P Smal (PSCH)||+5.62 (15.57%)|
|1.17%||N/A (SHMO)||+8.39 (18.37%)|
|0.98%||iShares Small Cap 600/BARRA Growth Index Fund (IJT)||+5.19 (6.39%)|
|0.96%||SPDR S&P 600 Small Cap Growth ETF (based on S&P SmallCap 600 G (SLYG)||+6.62 (5.39%)|
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.
Company Description (as filed with the SEC)
Questcor is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Our primary product is H.P. Acthar® Gel (repository corticotropin injection), or Acthar, an injectable drug that is approved by the U.S. Food and Drug Administration, or FDA, for the treatment of 19 indications. Of these 19 FDA approved indications, we currently generate substantially all of our net sales from the following indications: • Nephrotic Syndrome (NS): Acthar is indicated “to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. ... More ...